Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Dual activation of the glucagon-like peptide 1 (GLP-1) and glucagon receptor has the potential to lead to a novel therapy principle for the treatment of diabesity. Here, we report a series of novel peptides with dual activity on these receptors that were discovered by rational design. On the basis of sequence analysis and structure-based design, structural elements of glucagon were engineered into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual GLP-1/glucagon receptor activity. Detailed structure-activity relationship data are shown. Further modifications with unnatural and modified amino acids resulted in novel metabolically stable peptides that demonstrated a significant dose-dependent decrease in blood glucose in chronic studies in diabetic db/db mice and reduced body weight in diet-induced obese (DIO) mice. Structural analysis by NMR spectroscopy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptophan-cage fold motif that is responsible for favorable chemical and physical stability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
A hierarchical approach to all‐atom protein loop prediction
Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., & Friesner, R. A. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10613 · Cited by 2,504
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Designing a 20-residue protein
Neidigh, J. W., Fesinmeyer, R. M., & Andersen, N. H. (2002) · Nature Structural Biology · doi:10.1038/nsb798 · Cited by 793
A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis
KING, D. S., FIELDS, C. G., & FIELDS, G. B. (1990) · International Journal of Peptide and Protein Research · doi:10.1111/j.1399-3011.1990.tb00976.x · Cited by 725
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Structure of the human glucagon class B G-protein-coupled receptor
Siu, F. Y., He, M., de Graaf, C., Han, G. W., Yang, D., Zhang, Z., Zhou, C., Xu, Q., Wacker, D., Joseph, J. S., et al. (2013) · Nature · doi:10.1038/nature12393 · Cited by 379
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Diabesity: an overview of a rising epidemic
Farag, Y. M. K., & Gaballa, M. R. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq576 · Cited by 320
Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295
Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain
Runge, S., Thøgersen, H., Madsen, K., Lau, J., & Rudolph, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708740200 · Cited by 291
X-ray analysis of glucagon and its relationship to receptor binding
Sasaki, K., Dockerill, S., Adamiak, D. A., Tickle, I. J., & Blundell, T. (1975) · Nature · doi:10.1038/257751a0 · Cited by 286
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., et al. (2013) · Diabetes · doi:10.2337/db12-1116 · Cited by 245
Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070861j · Cited by 244
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
Neidigh, J. W., Fesinmeyer, R. M., Prickett, K. S., & Andersen, N. H. (2001) · Biochemistry · doi:10.1021/bi010902s · Cited by 204
Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3148 · Cited by 181
Effect of Glucagon on Food Intake and Body Weight in Man
Schulman, J. L., Carleton, J. L., Whitney, G., & Whitehorn, J. C. (1957) · Journal of Applied Physiology · doi:10.1152/jappl.1957.11.3.419 · Cited by 174
Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133
An appraisal of new variants of Dde amine protecting group for solid phase peptide synthesis
Chhabra, S. R., Hothi, B., Evans, D. J., White, P. D., Bycroft, B. W., & Chan, W. C. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(97)10828-0 · Cited by 127
Molecular basis for negative regulation of the glucagon receptor
Koth, C. M., Murray, J. M., Mukund, S., Madjidi, A., Minn, A., Clarke, H. J., Wong, T., Chiang, V., Luis, E., Estevez, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206734109 · Cited by 125
Exenatide: a review from pharmacology to clinical practice
Gentilella, R., Bianchi, C., Rossi, A., & Rotella, C. M. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.01018.x · Cited by 111
Majerle, A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg219 · Cited by 109
Peptide lipidation stabilizes structure to enhance biological function
Ward, B. P., Ottaway, N. L., Perez-Tilve, D., Ma, D., Gelfanov, V. M., Tschöp, M. H., & DiMarchi, R. D. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.08.008 · Cited by 101
Impact of weight gain on outcomes in type 2 diabetes
Ross, S. A., Dzida, G., Vora, J., Khunti, K., Kaiser, M., & Ligthelm, R. J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585396 · Cited by 91
Exenatide efficacy and safety: a systematic review
Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02790.x · Cited by 88
DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives
Santoprete, A., Capitò, E., Carrington, P. E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., et al. (2011) · Journal of Peptide Science · doi:10.1002/psc.1328 · Cited by 65
Optimization of the Native Glucagon Sequence for Medicinal Purposes
Chabenne, J. R., DiMarchi, M. A., Gelfanov, V. M., & DiMarchi, R. D. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400605 · Cited by 65
Kerr, B. D., Flatt, P. R., & Gault, V. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.010 · Cited by 56
Sal‐Man, N., Gerber, D., & Shai, Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503095200 · Cited by 56
Palmitoylation Increases the Kinase Activity of the G Protein-Coupled Receptor Kinase, GRK6
Stoffel, R. H., Inglese, J., Macrae, A. D., Lefkowitz, R. J., & Premont, R. T. (1998) · Biochemistry · doi:10.1021/bi981432d · Cited by 50
Staes, E., Absil, P.-A., Lins, L., Brasseur, R., Deleu, M., Lecouturier, N., Fiévez, V., Rieux, A. D., Mingeot‐Leclercq, M., Raussens, V., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.07.002 · Cited by 42
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
Self-citationExenatide: NMR/CD evaluation of the medium dependence of conformation and aggregation state
Hudson, F. M., & Andersen, N. H. (2004) · Biopolymers · doi:10.1002/bip.20126 · Cited by 38
Amon, M. A., Ali, M., Bender, V., Chan, Y., Tóth, I., & Manolios, N. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.013 · Cited by 37
Simonsen, L., Holst, J. J., Madsen, K., & Deacon, C. F. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2012.12.012 · Cited by 26
Lynch, A. M., Pathak, N., Pathak, V., O'Harte, F. P. M., Flatt, P. R., Irwin, N., & Gault, V. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3296-7 · Cited by 25
O'Harte, F. P. M., Ng, M., Lynch, A. M., Conlon, J. M., & Flatt, P. R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12713 · Cited by 22
O'Harte, F. P. M., Ng, M., Lynch, A. M., Conlon, J. M., & Flatt, P. R. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.05.012 · Cited by 20
Research works printed but not linked: 1
- Pegapamodutide, C16H27N3O7S, PubChem.https://pubchem.ncbi.nlm.nih.gov/compound/121494121#section=Chemical-and-Physical-Properties(accessed Mar 21, 2017) .
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Glucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218
Glucagon Receptor Signaling and Glucagon Resistance
Janah, L., Kjeldsen, S., Galsgaard, K. D., Winther-Sørensen, M., Stojanovska, E., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133314 · Cited by 203
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“3) and their efficacy translates from obese rodents to nonhuman primates and humans (Day et al., 2009; Pocai et al., 2009; Henderson et al., 2016; Tschop et al., 2016; Evers et al., 2017).”
BackgroundGLP-1: Molecular mechanisms and outcomes of a complex signaling system
Smith, N. K., Hackett, T. A., Galli, A., & Flynn, C. R. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.010 · Cited by 188
“, 2009), substantial progress has been made in producing these polyagonists, utilizing previous successful strategies including lipidation and building off the exendin backbone(Evers et al., 2017; Finan et al., 2013).”
Background
Metadata
- Authors
- Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., Lorenz, K., Kadereit, D., & Wagner, M.
- Affiliations
- Sanofi (Germany) (DE)
- Corresponding author
- Evers, Andreas
- Wagner, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-05-05
- Volume
- 60
- Issue
- 10
- Pages
- 4293-4303
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2608961189
- Semantic Scholar
- 8ff8b2b1e17044871e0c448672ec26ec4184b9c4
- Cited by
- 101
- References
- 47
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 4 · 2023: 6 · 2022: 14 · 2021: 10 · 2020: 22 · 2019: 18 · 2018: 16 · 2017: 3
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- exendin-4, GLP-1 receptor agonists, glucagon receptor agonist, dual receptor agonist, diabesity, structure-based design, structure-activity relationship, unnatural amino acids, modified amino acids, peptide stability, blood glucose reduction, db/db mice, diet-induced obesity, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Amino Acid Sequence, Animals, Blood Glucose, Body Weight, Female, Glucagon, Hypoglycemic Agents, Mice, Inbred C57BL, Mice, Obese, Obesity, Peptides, Structure-Activity Relationship, Swine, Venoms, Drug Design, Glucagon-Like Peptide 1, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.